
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics is set to make an impact with its innovative AlloSCOPE platform and robust pipeline of potential therapies for degenerative diseases. Despite the high risk associated with regenerative medicine, the company has shown promising signs of success with its OpRegen program, backed by external validation and support from Roche and Genentech. With a strategic focus on internal development and commercialization, we believe Lineage has the potential for long-term growth and potential for significant clinical wins, making it a solid buy for investors.
Bears say
Lineage Cell Therapeutics is facing challenges with its OpRegen program, as it has yet to yield significant improvements in visual and anatomical measures for patients with age-related macular degeneration (AMD). The company is currently relying on its AlloSCOPE platform and its TAI formulation for scalability, purity, and manufacturing of allogeneic CEnCs, but its dependence on these technologies may not be sustainable in the long run. Furthermore, the company's financial outlook remains uncertain due to the high expenses involved in developing and commercializing cell therapies, and its limited revenue potential from its current pipeline.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares